Kronik böbrek yetmezliği vakalarında anjiyotensin converting enzim inhibitörlerinin kullanımı ile TNF-alfa düzeyleri arasındaki ilişkinin araştırılması

The study of correlation between angiotensin converting enzyme inhibitor treatment and TNF-alpha in chronic renal failure

Haluk SARGIN, Mehmet ÇOBANOĞLU, Mustafa TEKÇE, Ali YAYLA, Demet TAŞAN, Banu PALAK

Özet

Kronik böbrek yetmezliği (KBY) tüm dünyada önde gelen morbidite ve mortalite sebeplerinden biridir. Çalışmamızda, anjiotensin konverting enzim inhibitörü (ACEI) tedavisi altında olan prediyaliz dönemdeki KBY'i olan hastalarda serum TNF-alpha seviyelerinin araştırılması amaçlanmıştır. Araştırmaya prediyaliz dönem KBY'li olan 48 hasta (kreatinin klirensi: 21,75±8 ml/dk ) alındı. Tüm hastalarda üre, kreatinin, albumin, serum TNF-alpha düzeyleri ölçüldü ve kreatinin klirensi hesaplandı. Çalışma sonucunda hastalar TNF-alpha sonuçlarına göre değerlendirildiğinde; ACEI kullanan KBY olan grupta (n:24), ACEI dışında antihipertansif kullanan (n:15) gruba göre TNF-alpha seviyeleri (29±14 vs 114±157, p

Abstract

Chronic renal failure (CRF) is one of the leading causes of morbidity and mortality all around the world. In this study, our aim was to determine serum TNF-alpha levels of pre-dialysis CRF patients who are on angiotensin converting enzyme inhibitor (ACEI) treatment. 48 pre-dialysis CRF patients were included in the study (creatinin clearance: 21,75±8 ml/min). Serum urea, creatinin, albumin, TNF-alpha levels of the patients were measured and their creatinin clearances were calculated. The patients were evaluated according to their serum TNF-alpha levels. The levels were significantly lower in the group that was on ACEI's (n=24) than the group that was on other anti-hypertensive drugs (n=15) (29±14; 1141157; p=0,05). There was also a statistically significant difference between the group that was on ACEI's and the group that was not on any anti-hypertensive medication (29±14, 114.4±65; p